About the Company
We do not have any company description for TENAX THERAPEUTICS, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TENX News
What's Going On With Tenax Therapeutics Shares?
Tenax Therapeutics, Inc. (NASDAQ:TENX) shares are trading higher by over 10% in the premarket session on Wednesday. The stock ...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on ...
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases ...
Tenax Therapeutics Granted Patent for Heart Treatment Drugs
Tenax Therapeutics (TENX) has released an update. Tenax Therapeutics, Inc. has announced a significant milestone with the US ...
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with ...
Tenax Therapeutics Inc TENX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with ...
Tenax Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Tenax Therapeutics Inc
A slump in renewable energy stocks means long-term opportunities aren't baked into some valuations.
Loading the latest forecasts...